@DoNotGoGently
Account based inUnited States
About this account
- Account based in
- United States
- Connected via
- United States App Store
Account-level information from X, not a live location or the device used for a specific post.
Biologist of aging. VP-Media at @bioagelabs. Producer and host of @bioagepodcast. Tweets, politics, & memes are my own. (he/him)
San Francisco
Joined February 2009
- Tweets17.2K
- Following1.2K
- Followers2.3K
- Likes21K
Pinned Tweet
Age is the primary risk factor for most cancers, but we devote far more resources to treating individual diseases than addressing the root cause.
Chris Patil retweeted
You really can't make this up.
Yesterday, I accused tech circles of overconfidence about AI in biology - e.g. blurting "AI will cure cancer in 5 years!" - without understanding clinical trials or basic pharmacology.
The result? A mass of comments from tech bros downplaying the need for clinical trials!
They basically doubled down on their overconfidence about a field they have not seriously studied or researched.
Well, bad news, guys - biology is not code. It is highly complex, high-noise, high-failure, R&D-heavy for wet labs, and full of painful unknowns and edge cases. Your Python skills and vibe coding don't give you insight into the nuances of drug development.
Thank goodness these people are not in charge of any serious biomedical research programs.
Many of them even advocate going straight from AI discovery to human trial, without the years of slow, expensive preclinical studies on mice.
Well, ~100 million mice die each year, for these studies. Most are euthanised for analysis of their tissues, but a substantial subset directly die as a result of candidate drugs being toxic.
Millions of people would literally perish every year, instead, if these overconfident tech X guys were to be in charge.
"AI will cure cancer within 5 years!"
Ahem - clinical trials?
"AI will reverse ageing within 7 years!"
Cool - clinical trials?!
"AI will be able to design and immediately synthesise a new drug for you, based on your DNA."
Haha sure - clinical trials??!
Guess the tech bros have decided that decade-long clinical trials are no longer important to AI drug discovery or wider pharmacology.
But it seems to come from a place of ignorance about basic pharmacology.
Do they not read up on basic facts, before confidently commenting on other peoples' fields of research?
What I deeply love about that viral post about the Doudna video on AI is that the poster so clearly used an LLM to write his clout-chasing, credentialist anti-AI screed
In new work, we lay out a vision for a high-level programming language for generative biology, called Proto.
Proto composes generative and predictive models spanning DNA, RNA, proteins, ligands, and their interactions, which we use to design complex biological functions. 1/n
Introducing LifeSciBench, a benchmark for measuring and improving how well AI supports real-world life science research.
Developed with 173 scientists from biotechnology and pharmaceutical research, LifeSciBench includes 750 expert-authored tasks across seven biological research workflows.
openai.com/index/introducing…
Heartbroken that I might literally never get to try Fable/Mythos (as a biotech person all I’d managed to do with it was get stepped down to Opus every time)
tell me you haven't actually tried to use Fable for biology without saying you haven't actually tried to use Fable for biology
Calling all researchers using Anthropic's AI model Claude: how are you using the new Claude Fable 5 model in your research?
We want to hear about the most impressive things it's built for your research projects or left you asking what the fuss is all about. Can it do things you couldn't do before? Let us know.
Chris Patil retweeted
Anthropic really needs to come up with a better solution than blanket refusals to any and all bio inquiries. It’s getting silly.
Chris Patil retweeted
I switched to the Moonshot models for biology about a month ago and it has done wonders for my cortisol levels
Kimi K2.6 is 5% less performant than Opus 4.8 but 100% less likely to think you're a bioterrorist for asking it to summarize a published article
"Nature has a well-established presence on Instagram and YouTube; a few months ago, we also joined TikTok."
Lol what year is this. This shit is decade+ out of date. Journals are a time machine to the past in every way
nature.com/articles/d41586-0…
"/goal revise your generated text until it yields a pangram score of 100"
After a hiatus, glad to be back in the chair producing new episodes of @BioAgePodcast — a show that features the people & companies advancing the science of human longevity and discovering drugs to extend healthspan.
For those of you who reached out to say you'd been missing the show — thanks for the encouragement and inspiration. And for those of you who haven't listened before, now's a great time to start.
"There is no such thing as ‘a’ senescent cell — just as there is no such thing as ‘a’ cancer cell."
Marco Quarta brought that premise to Translating Aging back in 2023. Three years later, the co-founder and CSO of @LifeRubedo returns to the show with the data to back it up: Phase 1b/2a results for RLS-1496, a first-in-class topical GPX4 modulator, with clean safety and significant efficacy signals across four skin indications. In our conversation, Marco also introduces his concept of a new drug class — senoadaptive therapeutics — that clear pathological cells and restore stressed-but-recoverable ones.
Plus: why GPX4 modulation could become the next GLP-1.
🎧
• Apple: podcasts.apple.com/us/podcas…
• Spotify: open.spotify.com/episode/7tk…
If this sounds enticing to you, I’ve got a bridge in Brooklyn I’d like to sell you
FinalDose is building the first programmable drug platform - a single smart drug molecule that finds diseased cells by their DNA and destroys them. They're starting with all cancers.
Congrats on the launch, @Jeffliu6068Liu, @sklin_lite, and @liyaohuang2!
ycombinator.com/launches/QKj…
Chris Patil retweeted
We're pleased to share additional positive interim Phase 1 data for BGE-102, our potent, orally available, brain-penetrant NLRP3 inhibitor — showing potential best-in-class hsCRP reduction in patients with elevated cardiovascular risk.
Read the release:
ir.bioagelabs.com/news-relea…
Key findings from our first MAD cohort in obese participants with elevated hsCRP:
• Rapid and profound reduction in hsCRP, a widely used marker of inflammatory cardiovascular risk: 86% median reduction at Day 14
• 93% of participants achieved hsCRP levels < 2 mg/L, the clinical threshold for reduced cardiovascular risk
• Broad anti-inflammatory effects: Significant reductions in IL-6 and fibrinogen, key independent markers of cardiovascular risk
• Well tolerated: Favorable safety profile with no dose-limiting toxicities
Path forward: Full Phase 1 data, including additional multiple ascending dose (MAD) cohorts in participants with obesity and elevated hsCRP, anticipated 1H26
Phase 2a study on track to initiate 1H26, with readout anticipated by year-end
Aging biology in action: Chronic inflammation is now recognized as a major driver of cardiovascular disease—on par with cholesterol—yet it remains undertreated. NLRP3 is a key driver of age-related inflammation, and BioAge's discovery platform showed that reduced NLRP3 activity is associated with healthy longevity. With the potential to deliver injectable-like inflammation reduction in a convenient oral therapy, BGE-102 could address a significant unmet need in cardiovascular risk management and beyond.
We look forward to sharing full Phase 1 results in the first half of this year!
Chris Patil retweeted
What will it take to turn the science of aging into new medicines that benefit millions of people? BioAge CEO and co-founder @kpfortney sat down with @TIME magazine’s @dmosbergen for an in-depth conversation about why targeting the biology of aging could transform how we treat metabolic disease—and why the field is at an inflection point.
The interview, published in TIME’s “Future of Living” series, covers topics including:
• 🔬 BioAge’s human-first approach — With decades of health records and biological samples, we can study what's different about people who age well and work backward to find drug targets.
• 💊 BGE-102, our lead NLRP3 inhibitor — Now in Phase 1 clinical trials, this once-daily oral therapy targets the chronic inflammation that drives cardiovascular risk as we age.
• 🏃 Apelin and the biology of exercise — We're developing drugs that mimic the molecular benefits of physical activity, with potential to help maintain healthy body composition during aging and therapeutic weight loss.
• 🤝 Why Big Pharma is leaning in — Our collaborations with Novartis and Lilly reflect growing recognition that aging biology offers a path to preventative medicines that address root causes of chronic disease.
"I'm expecting a lot to happen in the next 5 to 10 years," Kristen says. "The growth in the field has been tremendous, so that really bodes well."
Read the full interview: time.com/collections/future-…
Chris Patil retweeted
Why does ‘anti-aging’ hype sometimes drown out the best aging science? Why does Hollywood keep casting life-extension seekers as villains? And how can we educate the public about what the biology of aging makes possible?
Today at the 2025 Longevity Summit at @BuckInstitute, BioAge's VP-Media Chris Patil, PhD (@DoNotGoGently) is facilitating a conversation about the media narratives surrounding longevity science — and how we might tell them better.
Joining Chris on the panel will be:
- Zara Stone, Culture & Tech reporter at The San Francisco Standard
- Keith Comito, CEO & President, Lifespan Research Institute
- Gary J. Alan, Co-founder, ALSAE Foundation
One reason I've been resisting Gemini and sticking with Claude is the lack of consistent-context features like Projects. But I just had the thought that with Gemini 3 Pro under the hood and great RAG...is NotebookLM essentially Projects for Gemini?
Congratulations to the whole @bioagelabs team!
We're pleased to share positive interim Phase 1 data for BGE-102, our potent, orally available, brain-penetrant NLRP3 inhibitor being developed for patients with cardiovascular risk factors.
➡️Read the release: globenewswire.com/news-relea…
Key findings:
• Well tolerated across all SAD and MAD dose levels
Convenient dosing: Pharmacokinetic profile supports once-daily oral administration
• Robust target engagement: Achieved up to 98% suppression of IL-1β, a key upstream regulator of hsCRP and other inflammatory factors implicated in cardiovascular risk
• High brain penetration, enabling targeting of both central and peripheral inflammation
Path forward:
• We’re expanding the Phase 1 trial with additional MAD cohorts in participants with obesity and elevated cardiovascular risk factors enabling evaluation of biomarkers including hsCRP — data anticipated in 1H26
• A Phase 2a POC study focused cardiovascular risk factors in patients with obesity is anticipated to initiate in 2H26, with readout by end of year
Aging biology in action: NLRP3-driven inflammation is a hallmark of aging implicated in cardiovascular disease and metabolic dysfunction, and BioAge’s discovery platform showed that reduced NLRP3 activity is associated with healthy longevity. As a brain-penetrant inhibitor with potential best-in-class properties, BGE-102 has the potential to address age-related inflammation—offering a promising approach to treating metabolic disease and reducing cardiovascular risk.
We look forward to sharing additional data in 2026!
Looking forward to joining a panel on "Longevity in the Media" at the Longevity Summit next week!
We're excited to join @LongevityGL's fourth annual Longevity Summit, taking place next week December 9-10 at the @BuckInstitute.
BioAge COO and co-founder @eric_k_morgen, MD will deliver a keynote, and VP-Media Chris Patil, PhD (@DoNotGoGently) will join a panel discussion on longevity in the media. We're also proud to sponsor this year's event.
The Longevity Summit brings together the entire longevity ecosystem—entrepreneurs, biopharma companies, investors, researchers, and government—for two days of peer-to-peer learning focused on the business of longevity and the key areas of innovation needed to advance the field.
We're honored to share the stage with so many of the leaders working to extend human healthspan.
➡️ Registration is still open: longevitygl.org/longevity-su…
We look forward to seeing you there!
Chris Patil retweeted
The blockbuster GLP-1 drugs have revolutionized treatment of obesity and diabetes, but also have potential for unprecedented impact on overall healthspan. An editorial in @NatureBiotech asks: Could they be the first longevity medications?
They won’t be the last. Beyond GLP-1s, the editorial spotlights two promising strategies for treating chronic disease by targeting molecular mechanisms involved in human aging: blocking inflammaging by inhibiting the NLRP3 inflammasome, and activating exerkine signaling by activating the apelin receptor APJ.
BioAge’s pipeline covers both strategies — an APJ agonist program spanning both oral small molecules and long-acting biologics; and BGE-102, our oral brain-penetrant NLRP3 inhibitor with best-in-class potential, is currently in Phase 1 trials with initial data anticipated by year-end.
We're developing therapies that target the root biology of metabolic aging to treat and prevent chronic disease — and pioneering the next generation of longevity drugs.
Read the editorial: nature.com/articles/s41587-0…